Analyst Price Targets — SQZ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2022 8:48 am | — | Chardan Capital | $4.00 | $1.82 | Benzinga | Chardan Capital Maintains Buy on SQZ Biotechnologies, Lowers Price Target to $4 |
Latest News for SQZ
Serica Energy PLC (AIM:SQZ) drew renewed backing from Jefferies, which reinstated coverage on Tuesday as production growth prospects outweighed cuts to output and cash flow forecasts. In Wednesday trading, the shares stood at 275.21p, up 4%, while the broker reinstated coverage with a 'buy' rating and a 320p price target.
SQZ Biotechnologies (NYSE: SQZ - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Profitability This table compares SQZ Biotechnologies and
Serica Energy PLC (AIM:SQZ) has ruled out raising its 32.6683p-a-share offer for Pharos Energy (LSE:PHAR), holding its ground after rival bidder Ratio Petroleum Energy LP increased its proposal. Serica's offer comprises 28.6683p in cash plus a 4.0p special dividend.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SQZ.
U.S. House Trading
No House trades found for SQZ.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.